Eric Laugeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Laugeman has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Alex T. Price
Department of Radiation Oncology University Hospitals Seidman Cancer Center Case Western Reserve University School of Medicine Cleveland Ohio USA
8 shared publications - Hyun Kim
City of Hope National Medical Center, Los Angeles, CA
6 shared publications Sasa Mutic
Department of Radiation Oncology, Washington University, St. Louis, MO, USA
6 shared publicationsBin Cai
Department of Radiation Oncology, Washington University, St. Louis, MO, USA
5 shared publicationsLauren E. Henke
Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park Ave, St. Louis, MO 63108, USA
5 shared publicationsGeoffrey D. Hugo
Department of Radiation Oncology, Washington University School of Medicine in St. Louis, 4921 Parkview Place, Campus Box 8224, St. Louis, MO 63110, USA
4 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15  (1) , e84607
Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial
Background: Computed tomography (CT)–guided online stereotactic adaptive radiotherapy (CT-STAR) allows for ablative radiation doses to be delivered to selected patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) or unresectable pancreatic cancer. However, the use of CT-STAR to deliver an ablative dose to the pancreas while minimizing gastrointestinal (GI) side effects to reduce acute and late toxicity rates compared to historic controls has yet to be prospectively evaluated. Objective: The primary objective of this prospective, single-arm, multicenter phase 2 clinical trial (Adaptive Radiation Therapy Individualized Approach [ARTIA]–Pancreas) is to evaluate the rate of acute grade 3+ GI toxicity in patients with BR/LAPC treated with ablatively dosed CT-STAR compared to historical controls. Methods: Patients with histologically or cytologically confirmed BR, locally advanced, or medically inoperable pancreatic adenocarcinoma are eligible for participation. Consenting and eligible patients will be treated with CT-STAR, delivering 5 fractions over 1 to 2 weeks with daily adaptation based on anatomic changes observed with onboard cone beam CT imaging. The primary end point of this trial is the rate of acute patient-reported grade 3+ treatment-related GI toxicities, assessed at 90 days post CT-STAR and compared to a historical control rate of 20%. The key powered secondary end point is the rate of long-term patient-reported grade 3+ treatment-related GI toxicities, evaluated at 12 months post CT-STAR and compared to a historical control rate of 25%. Additional secondary end points include overall survival, local (in-field) control rates, and distant progression-free survival at 1 and 2 years post CT-STAR. Results: Study completion is anticipated in February 2029, and the final study results will be published upon completion of the study. Conclusions: ARTIA-Pancreas represents the first prospective phase 2 clinical trial to evaluate whether CT-STAR can reduce the rate of acute patient-reported GI toxicities in patients with BR/LAPC compared to historical controls. Findings from this clinical trial will provide evidence for safely and effectively incorporating ablatively dosed adaptive radiotherapy into treatment regimens for this population.
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15  (1) , e84607
Open AccessStereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial
Background: Computed tomography (CT)–guided online stereotactic adaptive radiotherapy (CT-STAR) allows for ablative radiation doses to be delivered to selected patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) or unresectable pancreatic cancer. However, the use of CT-STAR to deliver an ablative dose to the pancreas while minimizing gastrointestinal (GI) side effects to reduce acute and late toxicity rates compared to historic controls has yet to be prospectively evaluated. Objective: The primary objective of this prospective, single-arm, multicenter phase 2 clinical trial (Adaptive Radiation Therapy Individualized Approach [ARTIA]–Pancreas) is to evaluate the rate of acute grade 3+ GI toxicity in patients with BR/LAPC treated with ablatively dosed CT-STAR compared to historical controls. Methods: Patients with histologically or cytologically confirmed BR, locally advanced, or medically inoperable pancreatic adenocarcinoma are eligible for participation. Consenting and eligible patients will be treated with CT-STAR, delivering 5 fractions over 1 to 2 weeks with daily adaptation based on anatomic changes observed with onboard cone beam CT imaging. The primary end point of this trial is the rate of acute patient-reported grade 3+ treatment-related GI toxicities, assessed at 90 days post CT-STAR and compared to a historical control rate of 20%. The key powered secondary end point is the rate of long-term patient-reported grade 3+ treatment-related GI toxicities, evaluated at 12 months post CT-STAR and compared to a historical control rate of 25%. Additional secondary end points include overall survival, local (in-field) control rates, and distant progression-free survival at 1 and 2 years post CT-STAR. Results: Study completion is anticipated in February 2029, and the final study results will be published upon completion of the study. Conclusions: ARTIA-Pancreas represents the first prospective phase 2 clinical trial to evaluate whether CT-STAR can reduce the rate of acute patient-reported GI toxicities in patients with BR/LAPC compared to historical controls. Findings from this clinical trial will provide evidence for safely and effectively incorporating ablatively dosed adaptive radiotherapy into treatment regimens for this population.
- Open Access
- 15 July 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 54, 101012
Palliative expeditiously adaptive quad shot radiotherapy for head and neck cancers (PEAQ-RT)
- 15 July 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 54, 101012
Open AccessPalliative expeditiously adaptive quad shot radiotherapy for head and neck cancers (PEAQ-RT)
- 1 December 2024
- Published by Anderson Publishing, Ltd. in Applied Radiation Oncology
- Vol. 13  (4) , 6-16
Workflow Considerations for Implementing a Cone-Beam CT-Guided Adaptive Radiation Therapy Program
Cone-beam CT-guided adaptive radiation therapy (CTgART) is an emerging treatment paradigm that enables the delivery of online adaptive radiation therapy (ART) using CT-based onboard imaging. Our department installed and implemented a CTgART system in 2019 and has since developed workflows for the delivery of CTgART to a wide variety of disease sites. Herein we describe workflow considerations for implementing a CTgART program with a specific focus on the template-based treatment planning methodology that drives online adaptive plan creation on our department’s CTgART platform (Ethos; Varian Medical Systems, Palo Alto, CA). We describe disease-site-specific information for the delivery of CTgART to the thorax, abdomen, prostate, and bladder, and discuss future directions for this technology, which is becoming increasingly accessible and utilized in radiation oncology.
- 1 December 2024
- Published by Anderson Publishing, Ltd. in Applied Radiation Oncology
- Vol. 13  (4) , 6-16
Workflow Considerations for Implementing a Cone-Beam CT-Guided Adaptive Radiation Therapy Program
Cone-beam CT-guided adaptive radiation therapy (CTgART) is an emerging treatment paradigm that enables the delivery of online adaptive radiation therapy (ART) using CT-based onboard imaging. Our department installed and implemented a CTgART system in 2019 and has since developed workflows for the delivery of CTgART to a wide variety of disease sites. Herein we describe workflow considerations for implementing a CTgART program with a specific focus on the template-based treatment planning methodology that drives online adaptive plan creation on our department’s CTgART platform (Ethos; Varian Medical Systems, Palo Alto, CA). We describe disease-site-specific information for the delivery of CTgART to the thorax, abdomen, prostate, and bladder, and discuss future directions for this technology, which is becoming increasingly accessible and utilized in radiation oncology.
- Open Access
- 1 March 2024
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 30, 100242
The impact of an Advanced Practice Radiation Therapist contouring for a CBCT-based adaptive radiotherapy program
- 1 March 2024
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 30, 100242
Open AccessThe impact of an Advanced Practice Radiation Therapist contouring for a CBCT-based adaptive radiotherapy program
- Open Access
- 24 October 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100693
CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer
- 24 October 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100693
Open AccessCT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer
- Open Access
- 23 October 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100692
A feasibility trial of skin surface motion-gated stereotactic body radiotherapy for treatment of upper abdominal or lower thoracic targets using a novel O-ring gantry
- 23 October 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 44, 100692
Open AccessA feasibility trial of skin surface motion-gated stereotactic body radiotherapy for treatment of upper abdominal or lower thoracic targets using a novel O-ring gantry
- Open Access
- 9 September 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 28, 100491
In silico trial of simulation-free hippocampal-avoidance whole brain adaptive radiotherapy
- 9 September 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 28, 100491
Open AccessIn silico trial of simulation-free hippocampal-avoidance whole brain adaptive radiotherapy
- Open Access
- 21 July 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 42, 100661
Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program
- 21 July 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 42, 100661
Open AccessInitial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program
- Open Access
- 3 February 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 25, 100423
Patient specific contouring region of interest for abdominal stereotactic adaptive radiotherapy
- 3 February 2023
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 25, 100423
Open AccessPatient specific contouring region of interest for abdominal stereotactic adaptive radiotherapy
- 5 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 175, 144-151
Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer
- 5 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 175, 144-151
Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer